Thrombin-activatable fibrinolysis inhibitor in breast cancer patients

Medical Principles and Practice

Volumn 20, Issue 4, 2011, Pages 332-335

  Kaftan, O ^a   Kasapoglu, B ^a,b   Koroglu, M ^a   Kosar, A ^a   Yalcin, S K ^a  

^a FATIH UNIVERSITY   (Turkey)

^b NONE   (Turkey)

Author keywords

Breast cancer; Thrombin activatable fibrinolysis inhibitor

Indexed keywords

FIBRINOGEN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR;

ARTICLE; BREAST CANCER; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HOMEOSTASIS; HUMAN; HYPERCOAGULABILITY; STATISTICAL SIGNIFICANCE; THROMBOSIS;

BREAST NEOPLASMS; CARBOXYPEPTIDASE U; CASE-CONTROL STUDIES; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOGEN; FIBRINOLYSIS; HUMANS; TUMOR MARKERS, BIOLOGICAL;

EID: 79956094248     PISSN: 10117571     EISSN: 14230151     Source Type: Journal    
DOI: 10.1159/000324547     Document Type: Article

References (26)

1. United States National Institutes of Health, National Cancer Institute Breast Cancer 2007 report.
2. Dey S, Soliman AS: Cancer in the global health era: opportunities for the Middle East and Asia. Asia Pac J Public Health 2010;22:75-82.
3. Caine GJ, Stonelake PS, Rea D, Lip G Y H: Coagulopathic complications in breast cancer. Cancer 2003;98:1578-1586. (Pubitemid 37238612)
4. Ay C, Pabinger I: Tests predictive of thrombosis in cancer. Thromb Res 2010;125(suppl 2):S12-S15.
5. Wang W, Boffa PB, Bajzar L, Walker JB, Nesheim ME: A study of the mechanism of inhibition of fibrinolysis by activated thrombinactivable fibrinolysis inhibitor. J Biol Chem 1998;273:27176-27181. (Pubitemid 28500426)
6. Silveira A, Schatteman K, Goossens F, Moor E, Scharpe S, Strömqvist M, Hendriks D, Hamsten A: Plasma procarboxypeptidase U in men with symptomatic coronary artery disease. Thromb Haemost 2000;84:364-368.
7. Bajzar L, Manuel R, Nesheim ME: Purification and characterization of TAFI, a thrombinactivatable fibrinolysis inhibitor. J Biol Chem 1995;270:14477-14484.
8. Redlitz A, Tan AK, Eaton DL, Plow EF: Plasma carboxypeptidases as regulators of the plasminogen system. J Clin Invest 1995;96:2534-2538.
9. Juhan-Vague I, Renucci JF, Grimaux M, Morange PE, Gouvernet J, Gourmelin Y, Alessi MC: Thrombin-activable fibrinolysis inhibitor antigen levels and cardiovascular risk factors. Arteriscler Thromb Vasc Biol 2000;95:2855-2859.
10. Van Tilburg NH, Rosendal FR, Bertina RM: Thrombin-activable fibrinolysis. Blood 2000;95:2855-2859.
11. Eicheinger S, Schönauer V, Weltermann A, Minar E, Bialonczyk C, Hirschl M, Schneider B, Quehenberger P, Kyrle PA: Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism. Blood 2004;103:3773-3776. (Pubitemid 38596294)
12. Leebeek FW, van Goor MP, Guimares A H C, Brouwers GJ, De Maat MP, Dippel DW, Rijken DJ: High functional levels of thrombinactivatable fibrinolysis are associated with increased risk of first ischemic stroke. J Thromb Haemost 2005;3:2211-2218. (Pubitemid 41727199)
13. Montaner J, Ribo M, Monasterio J, Molina CA, Alvarez-Sabin J: Thrombin-activable fibrinolysis inhibitor antigen levels acute phase of ischemic stroke. Stroke 2003;34:1038-1040. (Pubitemid 36402986)
14. Hataji O, Taguchi O, Gabazza EC, Yuda H, D'Alessandro-Gabazza CN, Fujimoto H, Nishii Y, Hayashi T, Suzuki K, Adachi Y: Increased circulating levels of thrombin-activatable fibrinolysis inhibitor in lung cancer patients. Am J Hematol 2004;76:214-219. (Pubitemid 38828838)
15. Florian-Kujawski MR, Hoppensteadt D, Iqbal O, Demir M, Tobu M, Fareed D, Fareed J: Role of PAI-1 and TAFI in the mediation of fibrinolytic deficit in cancer patients: 2004 ASCO Annu Meet Proc (Post-Meeting Edition). J Clin Oncol 2004;22(suppl):9727.
16. Meijers JC, Oudijk EJ, Mosnier LO, Bos R, Bouma BN, Nieuwenhuis HK, Fijnheer R: Reduced activity of TAFI (thrombinactivatable fibrinolysis inhibitor) in acute promyelocytic leukaemia. Br J Haematol 2000;108:518-523. (Pubitemid 30196247)
17. Reijerkerk A, Meijers JC, Havik SR, Bouma BN, Voest EE, Gebbink MF: Tumor growth and metastasis are not affected in thrombinactivatable fibrinolysis inhibitor-deficient mice. J Thromb Haemost 2004;2:769-779. (Pubitemid 40185716)
18. Rickles FR, Edwards RL: Activation of blood coagulation in cancer: Trousseau's syndrome revisited. Blood 1983;62:14-31. (Pubitemid 13070586)
19. Caine GJ, Stonelake PS, Lip GY, Kehoe ST: Hypercoagulable state of malignancy. Neoplasia 2002;4:465-473.
20. Donati MB: Cancer and thrombosis: from phelegmasia alba dolens to transgenic mice. Thromb Haemost 1995;74:278-281.
21. Lip GY, Chin BS, Blann AD: Cancer and prothrombotic state. Lancet Oncol 2002;3:27-34.
22. Goad KE, Gralnick HR: Coagulation disorders in cancer. Hematol Oncol Clin North Am 1996;10:457-484. (Pubitemid 26097347)
23. Edwards RL, Rickles FR, Moritz TE: Abnormalities of blood coagulation tests in patients with cancer. Am J Clin Pathol 1987;88:596-602. (Pubitemid 18014618)
24. Luzatto G, Schafer AI: The prethrombotic state in cancer. Semin Oncol 1990;17:147-159. (Pubitemid 20131806)
25. Yigit E, Gönüllü G, Yücel I, Turgut M, Erdem D, Cakar B: Relation between hemostatic parameters and prognostic/predictive factors in breast cancer. Eur J Intern Med 2008;19:602-607.
26. Batschauer AP, Figueiredo CP, Bueno EC, Ribeiro MA, Dusse LM, Fernandes AP, Gomes KB, Carvalho MG: D-dimer as a possible prognostic marker of operable hormone receptor-negative breast cancer. Ann Oncol 2010;21:1267-1272.